Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Products In Brief

This article was originally published in The Gray Sheet

Executive Summary

A drug-eluting stent and prostate cancer assay are among newly approved devices.

You may also be interested in...



News In Brief

AHRQ tracks growth in knee replacement hospital admissions. Quest sells HemoCue business to Radiometer. More News in Brief

New Competition, Procedure Declines Challenge Abbott Vascular In Second Quarter

Abbott’s stent business was up against an approximately 5% decline in U.S. percutaneous coronary intervention procedures in the past quarter, on top of persistent pricing pressures and the U.S. launch earlier this year of Medtronic’s Resolute Integrity.

New Products In Brief

HeartWare ventricular assist device gains expanded labeling in Europe. Medigus gets 510(k) clearance for endoscopic GERD treatment. More new products.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT030978

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel